fluticasone propionate and salmeterol administered in a single inhaler (salmeterol/fluticasone propionate 50/100mug), compared …-inhaler salmeterol/fluticasone propionate treatment compared with FPIC and nFPIC may be lower than the commonly accepted benchmark value …-inhaler salmeterol/fluticasone propionate may also be more cost effective than leukotriene modifiers. …

-inhaler regimen with that of maintenance salmeterol/fluticasone propionate (Seretide(R)) plus salbutamol (albuterol) as needed …

corticosteroid/long-acting beta2-adrenoceptor agonist (beta2-agonist) combination (salmeterol/fluticasone propionate) versus usual … the combination of inhaled salmeterol/fluticasone propionate 50/500microg twice daily in poorly reversible COPD patients … salmeterol/fluticasone propionate reduced exacerbation frequency only (base case analysis), the estimated mean survival time …

corticosteroid) administered via a single powder inhalation device. The clinical effectiveness of salmeterol/fluticasone propionate … countries. In patients with asthma not controlled with inhaled corticosteroids, salmeterol/fluticasone propionate was associated … slightly higher with salmeterol/fluticasone propionate than with fluticasone propionate or montelukast monotherapy, salmeterol/fluticasone …

A budget impact model was used to estimate the effect of introducing inhaled salmeterol/fluticasone propionate … (or budesonide plus formoterol switch to combined salmeterol/fluticasone propionate, the anticipated annual savings would … shows that the introduction of inhaled salmeterol/fluticasone propionate combination is likely to have minimal impact on …

salmeterol/fluticasone propionate combination (SFC) 50/100mug or fluticasone propionate (FP) 100mug, administered twice daily via …

salmeterol/fluticasone propionate and 212 to montelukast. Treatment with salmeterol/fluticasone propionate resulted in a … propionate: 71% vs montelukast: 39%; p < 0.001] and percentage of SFDs (salmeterol/fluticasone propionate: 46.8% vs montelukast … salmeterol/fluticasone propionate group ($US5.03, 95% CI $US4.61 to $US5.50) compared with the montelukast group ($US8.25, 95% CI …

. Importantly, pharmacoeconomic analysis of several of these studies show that the salmeterol/fluticasone propionate combination is … management tended to be slightly higher with salmeterol/fluticasone propionate than with inhaled corticosteroid monotherapy, in … most cases mean cost-effectiveness ratios were lower (i.e. more favourable) for salmeterol/fluticasone propionate than …